The $28B Cannabis Blind Spot: Seniors, Edibles, and a Federal Cliff

Cannabis Is Aging. The Buying Experience Hasn't.

The cannabis industry spent fifteen years designing itself around one customer: young, culturally fluent, tolerance-aware, comfortable with slang, willing to experiment.

The growth is somewhere else now. It's a 68-year-old with arthritis. A 72-year-old widow who can't sleep. A 61-year-old recovering from knee surgery who keeps hearing cannabis might help but doesn't want to be high. The adult daughter searching Google at 11 p.m. because her mother bought a gummy at a dispensary and had a frightening night.

That customer doesn't want a neon menu, a budtender talking in strain names, or a package promising "cosmic relaxation." She wants plain English. She wants safety. She wants to know what this is, how much is too much, what to avoid, and what to ask her doctor.

The gap in the middle is a business. A trusted cannabis guidance brand for adults 60+ and the adult children helping them: a content, tool, email, and light-consulting operation focused on dosing literacy, product selection, and "start low, go slow" harm reduction. Lean to start. Durable if executed with the discipline of a medical brand rather than an affiliate blog. And sitting on top of a six-month federal regulatory cliff that's about to reshuffle the entire senior cannabis funnel.

Here's the opportunity:

The Numbers Have Already Moved

A research letter published in JAMA Internal Medicine in June 2025 found past-month cannabis use among adults 65 and older rose from 4.8% in 2021 to 7.0% in 2023, nearly a 46% increase in two years. The fastest growth came from a demographic the industry has historically ignored: college-educated, married, female, higher-income seniors, often with chronic conditions like diabetes, hypertension, cancer, or COPD.

Zoom out to the 50+ bracket and the lift is sharper. An AARP/University of Michigan poll released in September 2024 found 21% of adults 50+ used cannabis in the past year, up from 12% in 2021. The reasons skew medical: 68% for sleep, 63% for pain, 53% for mental health, 81% for general relaxation.

These aren't old stoners getting older. This is a wellness cohort discovering cannabis for the first time, with no one to ask.

The Pain Point: Stronger Product, Older Buyer, No Translator

Today's cannabis isn't the cannabis these buyers remember. Stanford Medicine warned in 2025 that current products are dramatically more potent than the "marijuana" most older adults recall, sharply raising the risk of accidental overconsumption. The shelf is unrecognizable: gummies, chocolates, drinks, tinctures, vape pens, concentrates, topicals, CBD ratios, hemp-derived THC, fast-onset edibles, and strain names that sound like energy drinks.

Edibles are where this gets dangerous. An edible can take 60 to 120 minutes to hit. A first-time user feels nothing after half an hour, eats more, then gets blindsided two hours later. A JAMA Internal Medicine study by Nathan Stall and colleagues at the University of Toronto tracked ED visits for cannabis poisoning among Ontario adults 65+ across three regulatory eras. Pre-legalization, the rate was 5.8 per 100,000. After edibles became legal for retail in January 2020, the rate hit 21.1 per 100,000. ED visits tripled. Over the eight-year window, more than 2,000 seniors landed in the ER for cannabis poisoning.

The drug-interaction risk is just as real and rarely discussed. THC inhibits the CYP2C9 enzyme that metabolizes warfarin, one of the most-prescribed drugs in the elderly. A review of published case reports found 6 of 7 patients on warfarin saw elevated INRs after using cannabis, with individual readings reaching above 10 in some cases, well into bleeding-risk territory. Most required warfarin dose reduction. CBD, often sold as the harmless cannabinoid, hits many of the same liver enzymes. A new senior buyer is walking into a high-potency, jargon-heavy retail system designed for someone else, usually while taking three to seven prescriptions no one at the dispensary will ask about.

Why Now: A Federal Cliff Is About to Reroute the Funnel

Senior demand is rising on a steep curve and isn't slowing. Format mix has shifted toward edibles, tinctures, capsules, topicals, and CBD-forward products, the wellness-shaped categories with the hardest dose, onset, and interaction profiles to understand without help.

The third trigger is the one most people miss. In November 2025, Congress passed Section 781 of the continuing appropriations bill, redefining "hemp" by total THC content rather than just delta-9. Effective November 12, 2026, any finished hemp product intended for human use must contain no more than 0.4 mg of total THC per container. That's a category-killer threshold for an industry estimated at $28–30 billion. Ohio's SB 56 banned intoxicating hemp products in December 2025. New Jersey is forcing accelerated inventory liquidation. Other states are following.

For seniors, this matters in a way the trade press hasn't framed clearly. Many of the older adults who quietly started experimenting with low-dose THC over the last two years did it through hemp-derived gummies shipped to their door. After November 2026, that channel disappears in most states. Their only legal option becomes a state-licensed dispensary, exactly the environment they've been avoiding. In six months, a wave of confused, medically complex first-time customers will be funneled into the most intimidating part of the cannabis market right when there is still no calm, trusted translator standing at the door.

Who Is Already Circling, and What They Are Missing

Competition exists, but it's product-led or telehealth-led, not education-led. Leafwell launched its $9.99/month Cannabis Care Program in July 2025 with a partnership reaching the Association of Mature American Citizens' two million members aged 50+, but Leafwell sells access to its own clinicians and partner dispensaries. EO Care wraps clinician phone support around its own product line, with full clinician-managed care plans at $14/month. Aunt Zelda's (now operating as The Oil Plant) serves seriously ill patients with full-spectrum extracts and personalized consults. Mary's Medicinals owns transdermal patches. AARP publishes occasional articles but can't run product comparison tools without putting its broader business at risk.

Each is real. None plays the role of the trusted plain-English guide. The gap is the same one Wirecutter exploited in consumer electronics, NerdWallet in personal finance, and GoodRx in pharmacy: an independent, calm, plainly written guide that helps a confused buyer make a safer decision and earns trust by being willing to say "don't buy this." Nobody owns that position in senior cannabis. The sellers are arriving. The translator hasn't shown up.

The Business: Cannabis After 60, Explained Slowly

The first version is a senior-first cannabis guidance brand. Think less High Times, more Consumer Reports meets AARP meets Wirecutter, with a careful health-literacy filter on top.

The site covers five domains: